Skip to content

Darunavir response did not differ by prior PI in POWER studies

Darunavir: negative interactions with Kaletra, Viagra and contraceptive pill reported

MK-0518: three-quarters of highly treated patients have undetectable viral load at 24 weeks

Novel NRTI elvucitabine active against HIV in a 7-day monotherapy study

Antibody to CCR5 receptor safe, effective, suitable for weekly dosing, preliminary study shows

No lipid increase with Merck integrase inhibitor at 24 weeks

Tibotec announces expanded access programme for new NNRTI TMC125

Panacos finds oral fusion inhibitors, provides development update on bevirimat

MK-0518 integrase inhibitor effective in treatment-naive patients